While receiving treatment at specialized centres lowers the risk of hospitalization among patients with idiopathic pulmonary fibrosis (IPF), being a former smoker and requiring oxygen therapy are both associated with a higher likelihood of hospitalization.
These are some of the findings of multiple studies that Boehringer Ingelheim will present about the management of pulmonary fibrosis associated with interstitial lung disease (IPF-ILD) at the 2021 American Thoracic Society (ATS) International Conference, held online, May 14–19.
All these studies are analyses of data gathered in the idiopathic pulmonary fibrosis – PROspective Outcomes (IPF-PRO) Registry (NCT01915511), one of the largest IPF patient registries that has been created to further understand the natural progression of IPF and current treatment approaches.